Table 1.
Study and Patient Characteristics
| Variable | No. | % |
|---|---|---|
| Study Characteristics | ||
|
| ||
| Clinical Trials | 17 | |
|
| ||
| Trial Phase | ||
| Phase I | 8 | 47.1 |
| Phase II | 6 | 35.3 |
| Phase III | 3 | 17.6 |
|
| ||
| Number of Oral Chemotherapy Agents | ||
| One | 14 | 82.0 |
| Two | 3 | 18.0 |
|
| ||
| Adherence Assessment Tool | ||
| Pill Diary | 15 | 88.0 |
| Verbal | 2 | 12.0 |
|
| ||
| Frequency of Adherence Assessment | ||
| Each cycle | 14 | 82.0 |
| Each study visit | 2 | 12.0 |
| Annually | 1 | 6.0 |
|
| ||
| Assessor of Adherence | ||
| Study nurse | 12 | 70.0 |
| Treating physician | 2 | 12.0 |
| Study coordinator | 2 | 12.0 |
| Unknown | 1 | 6.0 |
|
| ||
| Patient Demographics | ||
|
| ||
| Age | ||
| ≤ 65 years | 181 | 68 |
| > 65 years | 85 | 32 |
|
| ||
| Gender | ||
| Male | 121 | 45.5 |
| Female | 145 | 54.5 |
|
| ||
| Race | ||
| White | 248 | 96.1 |
| Other | 10 | 3.9 |
|
| ||
| Patients per Trial Phase | ||
| Phase I | 220 | 82.7 |
| Phase II–III | 46 | 17.3 |
|
| ||
| Number of Oral Chemotherapy Agents | ||
| One | 162 | 60.9 |
| Two | 104 | 39.1 |
|
| ||
| Performance Status | ||
| 0 | 95 | 35.7 |
| 1–2 | 171 | 64.3 |
|
| ||
| Type of Cancer | ||
| Colorectal | 64 | 24.1 |
| Breast | 42 | 15.8 |
| Neuroendocrine | 27 | 10.2 |
| Lung | 26 | 9.8 |
| Prostate | 18 | 6.8 |
| Ovarian | 11 | 4.2 |
| Head and Neck | 10 | 3.8 |
| Other | 67 | 25.3 |
|
| ||
| Cancer Stage | ||
| Localized | 20 | 7.6 |
| Metastatic | 243 | 92.4 |
|
| ||
| Distance from Medical Center | ||
| ≤90 miles | 194 | 73 |
| > 90 miles | 72 | 27 |
|
| ||
| Time on Study | ||
| ≤4 months | 202 | 76 |
| > 4 months | 64 | 24 |
|
| ||
| Best Response | ||
| Response (CR, PR, SD) | 96 | 37.1 |
| Progressive Disease | 126 | 48.6 |
| Toxicity | 31 | 12.0 |
| Lost to follow-up | 6 | 2.3 |